Study guide
11.3 Exercise-Induced Hypoglycemia Management (Rule of 15) & Hyperglycemia
AACVPR CCRP Certified Cardiac Rehab Professional Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Cardiac Rehabilitation Foundations
1.1 AACVPR CCRP Credential, Exam Specifications & Core Competencies 1.2 Phases of Cardiac Rehabilitation & Clinical Delivery Models 1.3 Interdisciplinary Team Roles, Clinical Scope of Practice & Safety
2 Chapter 2: Cardiovascular Anatomy, Physiology & Pathology
2.1 Cardiac Anatomy, Coronary Circulation & Hemodynamics 2.2 Atherosclerosis Pathogenesis, Acute Coronary Syndromes (ACS) & Revascularization 2.3 Heart Failure (HFrEF/HFpEF), Cardiomyopathies & Valvular Heart Disease 2.4 Electrical Interventions: Cardioversion, Catheter Ablation & Post-Procedure Rehabilitation
3 Chapter 3: Diagnostic Evaluation, ECG & Clinical Testing
3.1 Baseline Clinical Assessment & AACVPR Risk Stratification 3.2 12-Lead ECG Interpretation: Ischemia, Transmural Infarction & Conduction 3.3 Cardiac Arrhythmias, Conduction Blocks & Device Rhythms (Pacemakers/ICDs) 3.4 Graded Exercise Testing (GXT), Gas Exchange & Termination Criteria
4 Chapter 4: Patient-Centered Assessment: Education, Equity & Social Context
4.1 Learning Readiness: Health Literacy, Learning Styles & Communication Barriers 4.2 Social Determinants of Health, Culture & Spirituality in Cardiac Rehab 4.3 Sex- and Race-Based Differences in Cardiovascular Presentation & Outcomes 4.4 Substance Use Screening: Alcohol, Cannabis, Stimulants & Cardiac Risk
5 Chapter 5: Exercise Prescription & Aerobic Conditioning
5.1 FITT-VP Framework & Aerobic Exercise Intensity Calculation 5.2 Exercise Progression, Environmental Factors & Telemetry Monitoring Guidelines 5.3 High-Intensity Interval Training (HIIT) vs Moderate Continuous Training (MICT) 5.4 Home Exercise Program Design, Prescription & Independent Progression
6 Chapter 6: Exercise Physiology, Monitoring & Session Design
6.1 Health-Related Physical Fitness Components & Functional Capacity Testing 6.2 Acute Cardiovascular Responses to Aerobic Exercise: METs, Rate Pressure Product & VO₂ 6.3 Chronic Training Adaptations in Cardiac Patients 6.4 Structuring the Exercise Session: Warm-Up, Conditioning & Cool-Down 6.5 ECG Telemetry Setup: Skin Preparation, Electrode Placement & Artifact Troubleshooting 6.6 Pulse Oximetry, Exertional Desaturation & Supplemental Oxygen Titration
7 Chapter 7: Resistance, Flexibility & Exercise Safety
7.1 Resistance Training Guidelines, Hemodynamics & Sternal Precautions 7.2 Flexibility, Neuromotor Training & Special CR Populations 7.3 Exercise Contraindications, Adverse Signs/Symptoms & Emergency Protocols
8 Chapter 8: Physical Activity Counseling & Behavior Change
8.1 Physical Activity Guidelines, Sedentary Physiology & NEAT 8.2 Behavioral Change Theories: Transtheoretical Model & Social Cognitive Theory 8.3 Motivational Interviewing Principles & Resolving Ambivalence 8.4 SMART Goal Setting, Activity Tracking & Relapse Prevention
9 Chapter 9: Physical Activity Assessment & Real-World Activity Counseling
9.1 Physical Activity vs Exercise: Assessment Instruments, Logs & Wearables 9.2 Metabolic Requirements of Daily Life: Occupational, Recreational & Sexual Activity 9.3 Environmental & Situational Risk: Heat, Cold, Altitude, Air Quality & High-Risk Activities 9.4 Upper- vs Lower-Body Physiologic Demands & Modality Selection
10 Chapter 10: Hypertension & Blood Pressure Regulation
10.1 2017 ACC/AHA Hypertension Classification & Cardiovascular Risk 10.2 Antihypertensive Pharmacology & Exercise Hemodynamics 10.3 Exertional Blood Pressure Dynamics, Exertional Hypotension & Crisis 10.4 Home Blood Pressure Monitoring, Sodium Restriction & Lifestyle Interventions 10.5 Blood Pressure Measurement Technique, Device Validation & Renal Protection
11 Chapter 11: Diabetes Mellitus & Metabolic Regulation
11.1 Diabetes Pathophysiology, Diagnostic Criteria & Glycemic Targets 11.2 Antidiabetic Pharmacotherapy (Insulin, Sulfonylureas, SGLT2i, GLP-1 RA) 11.3 Exercise-Induced Hypoglycemia Management (Rule of 15) & Hyperglycemia 11.4 Diabetic Complications & Exercise Adaptations (Autonomic & Peripheral Neuropathy) 11.5 Blood Glucose Self-Monitoring, CGM Interpretation & Peri-Exercise Testing 11.6 Diabetic Foot Care, Skin Integrity & Footwear Assessment
12 Chapter 12: Blood Lipid Management & Atherosclerosis Prevention
12.1 Lipid Metabolism, Atherogenic Lipoproteins & Advanced Lipid Testing 12.2 Statin Therapy, Dosing Intensity & Secondary Prevention Targets 12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)
13 Chapter 13: Medical Nutrition Therapy & Dietary Patterns
13.1 Nutritional Assessment & Macronutrient Guidelines in Cardiovascular Disease 13.2 Cardioprotective Dietary Patterns: Mediterranean, DASH & Plant-Based 13.3 Dietary Lipids, Sodium, Soluble Fiber & Plant Stanols/Sterols 13.4 Clinical Scope: CR Professional Counseling Boundaries vs RD/RDN Referral
14 Chapter 14: Body Composition & Weight Management
14.1 Anthropometric Assessment: BMI, Waist Circumference & Obesity Paradox 14.2 Behavioral Weight Management, Energy Balance & Caloric Deficits 14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations
15 Chapter 15: Tobacco Cessation Interventions
15.1 Cardiovascular Pathophysiology of Tobacco, Nicotine & Secondhand Smoke 15.2 Clinical Cessation Frameworks: The 5 A's & 5 R's Models 15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion 15.4 Behavioral Counseling, Coping Strategies & Relapse Prevention
16 Chapter 16: Psychosocial Health, Screening & Behavioral Support
16.1 Psychosocial Risk Factors & Prognostic Impact in Heart Disease 16.2 Validated Screening Instruments: PHQ-9, GAD-7 & Administration 16.3 Evidence-Based Interventions: Stress Management, CBT Principles & Social Support 16.4 Crisis Protocols, Suicidal Ideation & Mental Health Referral Pathways 16.5 Psychotropic Pharmacology & Cardiac Safety 16.6 Sleep Disturbance, Chronic Pain & Somatic Comorbidity in Psychosocial Management
17 Chapter 17: Regulatory Compliance, Documentation & Program Outcomes
17.1 CMS Coverage Guidelines, Qualifying Diagnoses & Practitioner Supervision 17.2 Individualized Treatment Plan (ITP) Components, 30-Day Updates & Goals 17.3 AACVPR Outcome Domains & Program Certification Performance Measures 17.4 Program Certification, Quality Improvement & Medical Emergency Preparedness
11.3 Exercise-Induced Hypoglycemia Management (Rule of 15) & Hyperglycemia
Key Takeaways Explain This Topic AI
Hypoglycemia is defined as a blood glucose concentration <70 mg/dL (<3.9 mmol/L); during exercise, sympathetic beta-blockers mask classic autonomic warning signs (tachycardia, tremors, anxiety), leaving diaphoresis (cholinergically mediated sweating) as the primary visible clinical indicator.
The 'Rule of 15' mandates administering 15–20 grams of rapid-acting simple carbohydrate upon detecting glucose <70 mg/dL (or symptoms), waiting 15 minutes at complete physical rest, re-testing capillary glucose, and repeating until glucose is >=100 mg/dL.
Pre-exercise capillary glucose must be evaluated before every session: <100 mg/dL requires 15–30g of fast-acting carbohydrate before starting; 100–250 mg/dL is safe to initiate exercise; 250–300 mg/dL requires ketone screening; and >300 mg/dL mandates postponing exercise until corrected.
Skeletal muscle glucose uptake during exercise occurs via insulin-independent translocation of GLUT4 transporters driven by AMPK and intracellular calcium; following exercise, muscle and liver glycogen resynthesis enhances insulin sensitivity for 12 to 24 (up to 48) hours, predisposing patients to delayed nocturnal hypoglycemia.
Severe hypoglycemia involving neuroglycopenic stupor, seizure, or unconsciousness contraindicates oral intake due to aspiration hazard and requires immediate administration of parenteral glucagon (1 mg IM/SC or 3 mg nasal) or intravenous 50% dextrose (D50W).
Last updated: September 2026
11.3 Exercise-Induced Hypoglycemia Management (Rule of 15) & Hyperglycemia
Note
Acute Safety Imperative : Exercise-induced hypoglycemia is the most common acute medical emergency encountered in cardiac rehabilitation among patients treated with insulin or insulin secretagogues. Hypoglycemia triggers intense sympathoadrenal discharge that increases myocardial oxygen consumption ( M V O 2 MVO_2 M V O 2 ), induces coronary vasoconstriction, prolongs the corrected QT (QTc) interval, and predisposes patients with underlying CAD to fatal ventricular arrhythmias or acute myocardial ischemia. Standardized screening and immediate execution of the Rule of 15 are foundational clinical competencies.
Physical exercise fundamentally alters glucose kinetics. In healthy individuals, exquisite neuroendocrine feedback maintains plasma glucose within narrow physiological limits during exercise. In patients with diabetes treated with exogenous insulin or sulfonylureas, the loss of normal physiologic counterregulation creates a precarious metabolic balance, necessitating rigorous pre-exercise screening and immediate emergency protocols.
Exercise Physiology & Glucose Kinetics
Understanding how skeletal muscle clears glucose during and after physical activity provides the clinical rationale for glycemic monitoring protocols: Normal Exercise: Muscle Contraction ───> GLUT4 Translocation ───> Glucose Clearance
- ▲
- Insulin Drops & Glucagon Rises ────┘ (Balanced Hepatic Output = Euglycemia)
- Diabetic on Insulin: Muscle Contraction ───> GLUT4 Translocation ───> Glucose Clearance Surge
- ▲
- Exogenous Insulin High ────────────┴─ (Suppressed Hepatic Output = HYPOGLYCEMIA)
- Contraction-Mediated (Insulin-Independent) Glucose Uptake
During physical exertion, skeletal muscle glucose utilization increases by up to 20- to 30-fold over resting baselines:
Molecular Pathway : Repetitive mechanical sarcomere contraction triggers sarcoplasmic reticulum calcium release and activates calmodulin-dependent protein kinase (CaMK) and 5'-AMP-activated protein kinase (AMPK) .
Insulin-Independent GLUT4 Translocation : AMPK and calcium signaling cause GLUT4 storage vesicles to translocate and fuse with the sarcolemma and T-tubules entirely independently of insulin . This pathway remains completely functional even in patients with severe peripheral insulin resistance.
The Counterregulatory Response : In non-diabetic individuals, as muscle glucose clearance rises, endogenous pancreatic β \beta β -cell insulin secretion drops precipitously. Concurrently, counterregulatory hormones—primarily glucagon and epinephrine , supported by norepinephrine , cortisol , and growth hormone —surge, stimulating hepatic glycogenolysis and gluconeogenesis to match muscle uptake and preserve euglycemia ( 80 – 120 mg/dL 80\text{--}120\text{ mg/dL} 80 – 120 mg/dL ).
The Pathophysiological Failure in Treated Diabetes
When a patient treated with exogenous insulin or sulfonylureas exercises:
Circulating insulin concentrations do not decrease; in fact, insulin absorption may increase due to exercise hyperemia.
High circulating insulin completely blocks hepatic glycogenolysis and gluconeogenesis, preventing the liver from releasing glucose.
Concurrently, both the insulin-dependent and contraction-mediated (AMPK) pathways drive glucose out of the vascular space into myocytes simultaneously.
The result is a precipitous drop in blood glucose, leading to acute hypoglycemia.
Delayed Nocturnal Hypoglycemia: The 12- to 24-Hour Lag Effect
Following completion of exercise, skeletal muscle and hepatic glycogen reserves are severely depleted. To replenish these stores, glycogen synthase remains hyperactivated, and skeletal muscle exhibits markedly heightened insulin sensitivity for 12 to 24 hours (and up to 48 hours following unaccustomed or strenuous exercise) . As tissues continuously extract circulating glucose to resynthesize glycogen overnight, patients face a substantial risk of delayed nocturnal hypoglycemia hours after departing the rehabilitation facility. Clinicians must educate patients and caregivers to monitor late-evening glucose levels, consume a complex bedtime snack, or adjust evening basal insulin doses.
- Hypoglycemia: Definitions, Clinical Signs & Beta-Blocker Masking
- ADA Glycemic Staging
Level 1 (Hypoglycemia Alert Value) : Capillary blood glucose < 70 mg/dL < 70\text{ mg/dL} < 70 mg/dL ( < 3.9 mmol/L < 3.9\text{ mmol/L} < 3.9 mmol/L ) and ≥ 54 mg/dL \ge 54\text{ mg/dL} ≥ 54 mg/dL . Requires immediate treatment with fast-acting carbohydrates and adjustment of antidiabetic therapy.
Level 2 (Clinically Significant / Severe Hypoglycemia) : Capillary blood glucose < 54 mg/dL < 54\text{ mg/dL} < 54 mg/dL ( < 3.0 mmol/L < 3.0\text{ mmol/L} < 3.0 mmol/L ). Indicates serious neuroglycopenia requiring immediate carbohydrate administration.
Level 3 (Severe Hypoglycemic Event) : Characterized by severe cognitive impairment, altered mental status, seizure, or unconsciousness requiring external third-party assistance for resuscitation, regardless of the numerical glucose value.
Autonomic vs. Neuroglycopenic Symptomatology
The clinical presentation of acute hypoglycemia falls into two distinct physiological phases:
Symptom Category Physiological Mechanism Blood Glucose Threshold Characteristic Clinical Signs & Symptoms
Autonomic (Sympathoadrenal) Catecholamine (epinephrine, norepinephrine) release & sympathetic cholinergic activation ≈ 65 – 70 mg/dL \approx 65\text{--}70\text{ mg/dL} ≈ 65 – 70 mg/dL Diaphoresis (profuse sweating), tremors, tachycardia, palpitations, anxiety, pallor, hunger, piloerection
Neuroglycopenic Direct neuronal glucose deprivation in cerebral cortex & brainstem < 50 – 55 mg/dL < 50\text{--}55\text{ mg/dL} < 50 – 55 mg/dL Confusion, lightheadedness, dizziness, blurred/double vision, slurred speech, ataxia, irrational behavior, focal deficits, seizures, coma
The Critical Mechanism of Beta-Blocker Masking
More than 80% of cardiac rehabilitation participants are prescribed beta-adrenergic receptor antagonists (e.g., metoprolol, carvedilol, atenolol, bisoprolol) for secondary prevention following MI, CABG, or for HFrEF management.
The Masking Problem : Beta-blockers competitively antagonize β 1 \beta_1 β 1 and β 2 \beta_2 β 2 adrenergic receptors. When hypoglycemia triggers a counterregulatory catecholamine surge, beta-blockers suppress the classic warning signs: tachycardia, palpitations, tremors, and nervousness .
THE CLINICAL EXAM FACT—Diaphoresis Remains Unmasked : Eccrine sweat glands are anatomically part of the sympathetic nervous system but are innervated by sympathetic postganglionic cholinergic fibers releasing acetylcholine acting on muscarinic receptors . Because beta-blockers block adrenergic receptors, they do not inhibit muscarinic cholinergic signaling.
Clinical Implication : In a patient taking beta-blockers, profuse diaphoresis (unexplained, drenching cold sweat) is frequently the ONLY reliable autonomic warning sign of impending hypoglycemia . Unexplained sweating during or immediately after exercise in a beta-blocked patient must always be treated as acute hypoglycemia until proven otherwise by fingerstick glucose testing.
Hypoglycemia Unawareness : In patients with long-standing diabetes or diabetic autonomic neuropathy, repeated episodes of hypoglycemia blunt the sympathoadrenal response entirely. These patients transition directly from normal alertness to severe neuroglycopenic stupor or unconsciousness without warning.
Emergency Management: The "Rule of 15" Protocol
The Rule of 15 is the universal, standardized clinical protocol for treating mild-to-moderate (Level 1 and Level 2) hypoglycemia in conscious patients able to swallow safely: [ Capillary Glucose < 70 mg/dL or Symptomatic ]
- │
- ▼
- Step 1: Immediately HALT exercise; patient sits/reclines safely
- │
- ▼
- Step 2: Administer 15 to 20 grams of RAPID-ACTING simple carbohydrate
- (4 oz juice, 3-4 glucose tablets, 1 tube glucose gel)
- │
- ▼
- Step 3: Rest at complete physical rest for exactly 15 MINUTES
- │
- ▼
- Step 4: Re-test capillary fingerstick blood glucose
- │
- ┌─────────────┴─────────────┐
- ▼ ▼
- < 100 mg/dL >= 100 mg/dL
- REPEAT Step 2 RESOLVED: If next meal is >1 hr away,
- (Give another 15-20g) give complex carb + protein snack
- Step-by-Step Clinical Mechanics
Immediate Exercise Cessation : Stop exercise immediately. The patient must be seated or placed in a recumbent position to prevent falls or syncope.
Administer 15 to 20 Grams of Rapid-Acting Simple Carbohydrate :
4 oz 4\text{ oz} 4 oz ( 120 mL 120\text{ mL} 120 mL or 1 / 2 cup 1/2\text{ cup} 1/2 cup ) of orange juice, apple juice, or regular (non-diet) soda.
3 to 4 chewable glucose tablets ( 4 g 4\text{ g} 4 g glucose per tablet = 12 – 16 g 12\text{--}16\text{ g} 12 – 16 g ).
1 tube ( 15 g 15\text{ g} 15 g ) of oral glucose gel (administered along oral buccal mucosa).
5 to 6 hard candies (e.g., Lifesavers) chewed and swallowed.
1 tablespoon ( 15 mL 15\text{ mL} 15 mL ) of granulated sugar or honey.
FAT/PROTEIN RESTRICTION : Never administer high-fat foods such as chocolate candy bars, cookies, pastries, whole milk, or peanut butter. Dietary fats stimulate cholecystokinin release and significantly retard gastric emptying, delaying intestinal glucose absorption by 20 to 45 minutes and prolonging dangerous neuroglycopenia.
Wait 15 Minutes at Physical Rest : The patient must remain quiet and sedentary for 15 minutes to permit intestinal absorption and systemic distribution.
Re-Test Capillary Blood Glucose : After 15 minutes, perform a fingerstick capillary blood glucose test:
If blood glucose is < 100 mg/dL < 100\text{ mg/dL} < 100 mg/dL (or < 70 mg/dL < 70\text{ mg/dL} < 70 mg/dL ), administer an additional 15 – 20 g 15\text{--}20\text{ g} 15 – 20 g of rapid-acting carbohydrate, wait another 15 minutes, and re-test.
Repeat this cycle until capillary glucose is ≥ 100 mg/dL \ge 100\text{ mg/dL} ≥ 100 mg/dL .
Post-Recovery Sustaining Snack : Once blood glucose recovers to ≥ 100 mg/dL \ge 100\text{ mg/dL} ≥ 100 mg/dL , if the patient's next scheduled meal is more than 1 hour away , provide a snack containing complex carbohydrates and lean protein (e.g., graham crackers with peanut butter, whole-grain crackers with low-fat cheese, or half a turkey sandwich). This sustained-release fuel prevents rebound hypoglycemia driven by remaining circulating insulin.
Session Resumption : Exercise must not be resumed during that session once hypoglycemia requiring treatment has occurred.
Severe Hypoglycemia Protocol (Unconscious or Inability to Swallow)
Strict Oral Prohibition : Never attempt to administer oral liquids, tablets, or food into the mouth of a stuporous, seizing, or unconscious patient due to severe aspiration risk.
Emergency Medical Response : Activate the facility medical emergency response (Code Blue / Rapid Response) and alert the supervising physician.
Parenteral Resuscitation :
Glucagon : Administer 1 mg 1\text{ mg} 1 mg intramuscularly (IM) or subcutaneously (SC) , or 3 mg 3\text{ mg} 3 mg intranasally (Baqsimi) . Glucagon mobilizes hepatic glycogen stores within 10 to 15 minutes (note: glucagon may be ineffective in severe liver disease or prolonged starvation where hepatic glycogen is depleted).
Intravenous Dextrose : In medicalized outpatient clinics with IV access, administer 25 to 50 mL 25\text{ to }50\text{ mL} 25 to 50 mL of 50 % 50\% 50% Dextrose in Water (D50W) as a slow IV push over 2 to 5 minutes ( 12.5 to 25 grams 12.5\text{ to }25\text{ grams} 12.5 to 25 grams of elemental dextrose).
Pre-Exercise Blood Glucose Decision Matrix & Hyperglycemia Guidelines
To prevent acute intra-exercise crises, CR programs enforce standardized pre-exercise glucose triage thresholds for all diabetic participants:
Pre-Exercise Capillary Glucose Clinical Assessment & Risk Stratification Mandatory Clinical Action Protocol
< 100 mg/dL < 100\text{ mg/dL} < 100 mg/dL ( < 5.6 mmol/L < 5.6\text{ mmol/L} < 5.6 mmol/L ) High risk for acute exertional hypoglycemia Withhold exercise . Administer 15 – 30 g 15\text{--}30\text{ g} 15 – 30 g fast-acting carbohydrate . Re-test in 15–20 min; do NOT initiate exercise until glucose reaches ≥ 100 mg/dL \ge 100\text{ mg/dL} ≥ 100 mg/dL .
100 – 250 mg/dL 100\text{--}250\text{ mg/dL} 100 – 250 mg/dL ( 5.6 – 13.9 mmol/L 5.6\text{--}13.9\text{ mmol/L} 5.6 – 13.9 mmol/L ) Optimal, safe glycemic zone Proceed with exercise session as prescribed. No carbohydrate supplementation required.
250 – 300 mg/dL 250\text{--}300\text{ mg/dL} 250 – 300 mg/dL ( 13.9 – 16.7 mmol/L 13.9\text{--}16.7\text{ mmol/L} 13.9 – 16.7 mmol/L ) Borderline hyperglycemia; evaluate ketosis risk Screen for blood or urine ketones (mandatory in T1D or SGLT2i users).; - Ketones Negative/Trace : Proceed with low-to-moderate intensity exercise; ensure hydration; recheck in 20 min.; - Ketones Moderate/Large : Contraindicated . Withhold exercise.
> 300 mg/dL > 300\text{ mg/dL} > 300 mg/dL ( > 16.7 mmol/L > 16.7\text{ mmol/L} > 16.7 mmol/L ) Severe hyperglycemia; risk of DKA/HHS and dehydration Exercise is temporarily contraindicated . Withhold exercise. Hydrate with water; consult medical director; administer corrective insulin per orders; re-evaluate once < 250 – 300 mg/dL < 250\text{--}300\text{ mg/dL} < 250 – 300 mg/dL .
The Pathophysiological Danger of Exercising with Hyperglycemia and Ketosis
Clinicians often mistakenly assume that exercise will always "burn off" high blood glucose. However, when marked hyperglycemia ( > 250 – 300 mg/dL > 250\text{--}300\text{ mg/dL} > 250 – 300 mg/dL ) occurs in the setting of insulin deficiency :
The patient lacks sufficient circulating insulin to permit cellular glucose entry.
Physical exercise provokes a massive counterregulatory catecholamine, cortisol, and glucagon surge.
These counterregulatory hormones stimulate vigorous hepatic glycogenolysis, gluconeogenesis, and adipose tissue lipolysis .
Rather than lowering glucose, exercise in an insulin-deficient state drives blood glucose higher, accelerates ketone synthesis, triggers severe osmotic diuresis, and can rapidly precipitate fulminant Diabetic Ketoacidosis (DKA) .
Realistic Clinical Scenario: Complex In-Session Hypoglycemic Rescue
Clinical Scenario : A 58-year-old male with a history of anterior STEMI status-post PCI to the LAD 4 weeks ago and long-standing Type 2 diabetes presents for his sixth Phase II cardiac rehabilitation session. His home medications include carvedilol 12.5 mg 12.5\text{ mg} 12.5 mg BID, lisinopril 10 mg 10\text{ mg} 10 mg daily, atorvastatin 80 mg 80\text{ mg} 80 mg daily, and insulin glargine (Lantus) 34 units 34\text{ units} 34 units at bedtime plus insulin lispro (Humalog) with meals.
Intake Evaluation & Progression :
Pre-exercise fingerstick capillary glucose at 08:45 is 92 mg/dL 92\text{ mg/dL} 92 mg/dL .
Recognizing that glucose is < 100 mg/dL < 100\text{ mg/dL} < 100 mg/dL in an insulin-treated patient, the exercise physiologist provides 4 oz 4\text{ oz} 4 oz of apple juice ( 15 g 15\text{ g} 15 g simple carbohydrate). At 09:05, repeat fingerstick reads 116 mg/dL 116\text{ mg/dL} 116 mg/dL , clearing him to begin.
At minute 22 of continuous treadmill walking ( 2.8 mph 2.8\text{ mph} 2.8 mph , 2.0 % grade 2.0\%\text{ grade} 2.0% grade ), the nurse observes that the patient is sweating profusely, drenching his collar, and demonstrating a mild unsteady gait. His telemetry ECG shows sinus rhythm at 72 bpm 72\text{ bpm} 72 bpm without ST changes. He denies chest pain, palpitations, or nervousness, stating, "I'm just a little warm from the workout."
Clinical Management :
Clinical Recognition : The nurse recognizes that carvedilol blunts tachycardia, tremors, and anxiety, but diaphoresis is unmasked. The nurse immediately terminates treadmill walking and assists him into a wheelchair.
Immediate Testing : Capillary blood glucose is tested immediately, revealing 58 mg/dL 58\text{ mg/dL} 58 mg/dL (Level 2 hypoglycemia).
Rule of 15 Execution : The clinician administers 15 g 15\text{ g} 15 g of oral glucose gel. The patient rests in a quiet room for 15 minutes. At 15 minutes, repeat capillary glucose is 84 mg/dL 84\text{ mg/dL} 84 mg/dL (still < 100 mg/dL < 100\text{ mg/dL} < 100 mg/dL ). The clinician administers a second 15 g 15\text{ g} 15 g dose of glucose gel.
Resolution & Stabilization : At 30 minutes, capillary glucose rises to 118 mg/dL 118\text{ mg/dL} 118 mg/dL . Because his lunch is 2 hours away, the team provides 4 peanut butter crackers ( 16 g 16\text{ g} 16 g complex carb + 4 g 4\text{ g} 4 g protein). Exercise is aborted for the day.
Prevention Education : The clinician counsels the patient regarding the 12- to 24-hour delayed nocturnal hypoglycemia risk, instructs him to verify glucose at bedtime, and contacts his endocrinologist to consider a 10% reduction in basal insulin on rehabilitation days.